{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Davis SK"],"funding":["Paul Ramsay Foundation","Howard Hughes Medical Institute","National Health and Medical Research Council","Wellcome Trust","Australian Research Council"],"pagination":["e1424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9588388"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(10)"],"pubmed_abstract":["<h4>Objectives</h4>Following infection with SARS-CoV-2, virus-specific antibodies are generated, which can both neutralise virions and clear infection via Fc effector functions. The importance of IgG antibodies for protection and control of SARS-CoV-2 has been extensively reported. By comparison, other antibody isotypes including IgA have been poorly characterised.<h4>Methods</h4>Here, we characterised plasma IgA from 41 early convalescent COVID-19 subjects for neutralisation and Fc effector functions.<h4>Results</h4>Convalescent plasma IgA from > 60% of the cohort had the capacity to inhibit the interaction between wild-type RBD and ACE2. Furthermore, a third of the cohort induced stronger IgA-mediated ACE2 inhibition than matched IgG when tested at equivalent concentrations. Plasma IgA a"],"journal":["Clinical & translational immunology"],"pubmed_title":["Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma."],"pmcid":["PMC9588388"],"funding_grant_id":["208693/Z/17/Z"],"pubmed_authors":["Godfrey DI","Pymm P","Redmond SJ","Kent SJ","Adair A","Haycroft ER","Davis SK","Wheatley AK","Chung AW","Selva KJ","Lopez E","Tham WH","Lee WS","Juno JA","Gherardin NA"],"additional_accession":[]},"is_claimable":false,"name":"Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma.","description":"<h4>Objectives</h4>Following infection with SARS-CoV-2, virus-specific antibodies are generated, which can both neutralise virions and clear infection via Fc effector functions. The importance of IgG antibodies for protection and control of SARS-CoV-2 has been extensively reported. By comparison, other antibody isotypes including IgA have been poorly characterised.<h4>Methods</h4>Here, we characterised plasma IgA from 41 early convalescent COVID-19 subjects for neutralisation and Fc effector functions.<h4>Results</h4>Convalescent plasma IgA from > 60% of the cohort had the capacity to inhibit the interaction between wild-type RBD and ACE2. Furthermore, a third of the cohort induced stronger IgA-mediated ACE2 inhibition than matched IgG when tested at equivalent concentrations. Plasma IgA a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-12T19:28:02.853Z","creation":"2025-04-05T10:06:46.456Z"},"accession":"S-EPMC9588388","cross_references":{"pubmed":["36299410"],"doi":["10.1002/cti2.1424"]}}